会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    • 非核苷酸逆转录酶抑制剂
    • WO02076982A3
    • 2002-12-12
    • PCT/CA0200385
    • 2002-03-21
    • BOEHRINGER INGELHEIM CA LTDOGILVIE WILLIAM WDEZIEL ROBERTNAUD JULIEO'MEARA JEFFREY
    • OGILVIE WILLIAM WDEZIEL ROBERTNAUD JULIEO'MEARA JEFFREY
    • A61K31/551A61P31/14A61P31/18A61P43/00C07D471/14A61K31/55
    • C07D471/14
    • A compound of formula (I) wherein A is a connecting chain of (C1-3) alkyl; B is O or S; R is H, (C1-6) alkyl, halo, CF3, or OR wherein R is H or (C1-6)alkyl; R is H or Me; R is H or Me; R is H, (C1-4) alkyl, (C3-4) cycloalkyl and (C1-4)alkyl(C3-7)cycloalkyl; W is selected form formula (i), (ii) or (iii) wherein, a) one of Y is SO2 and the other Y is NR , provided that both are not the same, wherein R is H, (C1-6)alkyl,(C3-6) cycloalkyl, the alkyl being substituted, COR , COOR or CONR R ; and each R is H, (C1-4) alkyl, (C3-6) cycloalkyl, or (C1-4) alkyl-(C3-6) cycloalkyl; or b) E is CR R wherein R and R is H, or alkyl and J is CH2; or J is CR R and E is CH2, and the dotted line represents a single bond; or c) E is C(O) and J is CR R or J is C(O) and E is CR R and the dotted line represents a single bond; or d) E and J are CR R and the dotted line represents a double bond. Compounds of formula I have activity against HIV WT and double mutant strains.
    • 式(I)的化合物,其中A是(C 1-3)烷基的连接链; B是O或S; R 1是H,(C 1-6)烷基,卤素,CF 3或OR 1a,其中R 1a是H或(C 1-6)烷基; R 2是H或Me; R 3是H或Me; R 4是H,(C 1-4)烷基,(C 3-8)环烷基和(C 1-4)烷基(C 3-7)环烷基; W选自式(i),(ii)或(iii),其中a)Y中的一个是SO 2,另一个Y是NR 5,条件是两者不同,其中R 5是H ,(C 1-6)烷基,(C 3-6)环烷基,取代的烷基,COR 50,COOR 5或CONR 5 R 5; 并且每个R 8是H,(C 1-4)烷基,(C 3-6)环烷基或(C 1-4)烷基 - (C 3-6)环烷基; 或b)E是CR 8a R 8b,其中R 8a和R 8b是H,或烷基,J是CH 2; 或J为CR 8a R 8b且E为CH 2,虚线表示单键; 或c)E是C(O),J是CR 8a R 8b或J是C(O),E是CR 8a R 8b,虚线代表单键; 或d)E和J是CR 8a R 8b,虚线表示双键。 式I化合物具有抗HIV WT和双突变株的活性。
    • 2. 发明申请
    • INHIBITORS OF PAPILLOMA VIRUS
    • PAPILLOMA病毒的抑制剂
    • WO0250082A3
    • 2002-12-19
    • PCT/CA0101800
    • 2001-12-14
    • BOEHRINGER INGELHEIM CA LTDYOAKIM CHRISTIANEHACHE BRUNOOGILVIE WILLIAM WO'MEARA JEFFREYWHITE PETERGOUDREAU NATHALIE
    • YOAKIM CHRISTIANEHACHE BRUNOOGILVIE WILLIAM WO'MEARA JEFFREYWHITE PETERGOUDREAU NATHALIE
    • A61K31/34A61K31/343A61K31/36A61K31/381A61K31/407A61K31/4245A61K31/428A61K31/4725A61K31/5377A61P31/12A61P31/20C07D307/94C07D405/12C07D407/10C07D407/12C07D407/14C07D409/12C07D413/12C07D417/12C07D491/04C07D491/107C07D493/04C07D493/10C07D495/10C07D495/12C07D495/14C07D495/20
    • C07D405/12C07D307/94C07D407/12C07D407/14C07D413/12C07D417/12C07D491/04C07D493/04C07D493/10C07D495/12
    • A compound of formula (I) or its enantiomers or diastereoisomers thereof:wherein: A is a 5- or 6-membered homocyclic ring, or a 5- or 6-membered heterocyclic ring containing 1 or more heteroatoms; X is H and W is OH; or X and W together form a carbonyl group or an epoxide; R1 is H; or one or two substituents; Y is phenyl optionally mono- or di-substituted, said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom; or Y is a heterocycle (Het) containing one or more heteroatoms, said Het optionally mono- or di-substituted, said Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom; or Y is ethylene-phenyl, said ethylene moiety being optionally mono-substituted, wherein said phenyl ring is optionally mono- or di-substituted, said phenyl ring being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom; or Y is ethylene-Het, said ethylene moiety being optionally mono-substituted, wherein Het is optionally mono- or di-substituted; said Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom; R3 is selected from the group consisting of: lower alkyl, lower cycloalkyl, lower alkylene, aryl or lower aralkyl, all of which optionally mono- or di-substituted, said lower cycloalkyl, aryl, lower aralkyl or Het being optionally fused with a saturated or unsaturated 4 to 6-membered ring optionally containing a heteroatom; and R4 is a carboxylic acid, a salt or an ester thereof.The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.
    • 式(I)化合物或其对映异构体或非对映异构体:其中:A为5-或6-元级环,或含有1个或多个杂原子的5或6元杂环; X是H,W是OH; 或X和W一起形成羰基或环氧化物; R1是H; 或一个或两个取代基; Y是任选被一或二取代的苯基,所述苯环任选地与任选地含有杂原子的饱和或不饱和的4至6元环稠合; 或Y是含有一个或多个杂原子的杂环(Het),所述Het任选地被单取代或二取代,所述Het任选地与任选地含有杂原子的饱和或不饱和的4至6元环稠合; 或Y是乙烯 - 苯基,所述乙烯部分任选被单取代,其中所述苯环任选被一或二取代,所述苯环任选与饱和或不饱和的4至6元环稠合,任选地含有杂原子 ; 或Y是乙烯-Het,所述乙烯部分任选是单取代的,其中Het任选被一或二取代; 所述Het任选地与任选地含有杂原子的饱和或不饱和的4至6元环稠合; R 3选自:低级烷基,低级环烷基,低级亚烷基,芳基或低级芳烷基,所有这些可任选被一或二取代,所述低级环烷基,芳基,低级芳烷基或Het任选地与饱和的 或任选含有杂原子的不饱和4至6元环; 并且R 4是羧酸,其盐或酯。本发明的化合物可以用作乳头瘤病毒E1-E2-DNA复合物的抑制剂。 本发明还提供了治疗或预防人乳头状瘤病毒感染的方法。
    • 3. 发明专利
    • INHIBIDORES NO NUCLEOSIDOS DE TRANSCRIPTASA INVERESA.
    • ES2268499T3
    • 2007-03-16
    • ES03816107
    • 2003-09-15
    • BOEHRINGER INGELHEIM CA LTD
    • YOAKIM CHRISTIANEMALENFANT ERICTHAVONEKHAM BOUNKHAMOGILVIE WILLIAM WDEZIEL ROBERT
    • C07D471/14A61K31/55A61P31/18C07D221/00C07D243/00
    • Un compuesto representado por la fórmula I: en la que R1 se elige entre el grupo formado por H, halógeno, alquilo C1-4, O-alquilo C1-6 y haloalquilo; R2 es H o alquilo C1-4; R3 es H o alquilo C1-4; R4 es alquilo C1-4, (alquil C1-4)-cicloalquilo C3-7 o ciclo- alquilo C3-7 y Q es un heterociclo saturado de 5 ó 6 eslabones, fusionado con un fenilo, que tiene uno o dos heteroátomos elegidos entre O y N, dicho Q se elige entre el grupo formado por: a) en el que uno de E y G es C(O) y el otro es NR5, en el que R5 se elige entre el grupo formado por H, hidroxi y alquilo C1-4 sin sustituir o sustituido por piridinilmetilo, (N-óxido de piridinil)metilo o C(O)OR6, en el que R6 es H o alquilo C1-4; y cada R7 con independencia de su aparición es H, Me o Et; o b) en el que E es NR8, en el que R8 es H, alquilo C1-4 sin sus- tituir o sustituido por C(O)OR9, en el que R9 es H o alquilo C1-4; o c) en el que D y G son NR10, en el que cada R10 con independencia de su aparición es H o alquilo C1-4 sin sustituir o sustituir por C(O)OR11, en el que R11 es H o alquilo C1-4; o d) en el que uno de L, M, Y y Z es NR12, en el que R12 es H, alquilo C1-4 sin sustituir o sustituido por C(O)OR12x, en el que R12x es H o alquilo C1-4; una de las posiciones restantes de L, M, Y y Z contiguas a NR12 es C(O); y las dos posiciones restantes son en cada caso CR13R13, en el que cada R13 con independencia de su aparición es H, Me o Et; o e) en el que tres posiciones contiguas de L, M, Y y Z (a saber: L-M-Y o M-Y-Z) significan NR14-C(O)-O- o -NR15-C(O)-NR16-, en los que R14, R15 y R16 significan en cada caso H o alquilo C1-4 sin sustituir o sustituido por C(O)OR17, en el que R17 es H o alquilo C1-4; y la posición restante de L o de Z es CR18R18, en el que cada R18 es H, Me o Et; o una sal farmacéuticamente aceptable o un profármaco del mismo.